Drugmaker Incyte Corp reported fourth-quarter revenue above Wall Street estimates on Monday, boosted by strong demand for its key blood-cancer drug Jakafi and skin-disorder treatment Opzelura.

We think the strategy to find more effective combination therapies in hematology and build a larger oncology and dermatology portfolio is solid, although we're waiting for key data before assuming the ...

Incyte is preparing to take an oral JAK inhibitor into phase 3 trials for the skin depigmentation disease ... used to treat myelofibrosis, polycythemia vera, and graft-versus-host disease, saw ...

It’s winter in the Northern Hemisphere, and for many people that means having the spotlight on your body’s largest organ—skin. In cold climates the skin can become substantially drier ...

Feb. 3, 2025 — Psoriasis is a chronic skin disease that manifests itself mainly with skin symptoms (dryness, itching, scaly skin, abnormal patches and plaques). It affects about 2% of the ...

Panelists discuss how myelofibrosis can evolve following initial treatment, examining common patterns of disease progression and strategies for adapting therapeutic approaches based on individual ...

Jan. 14, 2025 — A team of researchers has developed a new biomaterial with high potential in in the treatment of bone lesions or minimal residual disease in multiple myeloma patients. The ...

The integumentary system is the body’s outermost layer. Composed of skin, hair, nails, glands, and nerves, its main job is to protect your insides from elements in your environment, like pollution and ...

Multiple myeloma is part of the spectrum of diseases ranging from MGUS to plasma cell leukemia, and similar to MGUS, is characterized by proliferation of a plasma cell clone and subsequent ...